SHP-465
- Generic Name
- SHP-465
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 24
- Registration Number
- NCT03327402
- Locations
- ๐บ๐ธ
Clinical Neuroscience Solutions Inc, Memphis, Tennessee, United States
๐บ๐ธOhio Pediatric Research Assn Inc, Dayton, Ohio, United States
๐บ๐ธProfessional Psychiatric Services (PPS), Mason, Ohio, United States
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 89
- Registration Number
- NCT03325881
- Locations
- ๐บ๐ธ
Pedia Research, LLC, Owensboro, Kentucky, United States
๐บ๐ธAcevedo Medical Group, Miami, Florida, United States
๐บ๐ธAdvanced Research Center, Anaheim, California, United States
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 141
- Registration Number
- NCT03325894
- Locations
- ๐บ๐ธ
PEWMD, PA, ARCSM, PLLC, PRP, Inc., Little Rock, Arkansas, United States
๐บ๐ธNeuroscientific Insights, Rockville, Maryland, United States
๐บ๐ธNeurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 264
- Registration Number
- NCT02466425
- Locations
- ๐บ๐ธ
Florida Clinical Research Center, Llc, Bradenton, Florida, United States
๐บ๐ธOmega Medical Research, Warwick, Rhode Island, United States
๐บ๐ธRed Oak Psychiatry Associates, Pa, Houston, Texas, United States
The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 86
- Registration Number
- NCT00928148
A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Shire
- Registration Number
- NCT00458445
- Locations
- ๐บ๐ธ
Meridien Research, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.